Welcome to Seeking Alpha's Wall Street Breakfast, where we cover the top news for investors every morning.

It's good to have you here on this Wednesday, February 11th. I'm Julie Morgan.

Beta Technologies is up nearly 19% pre-market following a regulatory filing showing that Amazon.com has taken a 5.3% stake in

the electric aviation firm. According to a Schedule 13G filed with the Securities and Exchange

Commission, Amazon beneficially owns more than 11 million shares of beta technologies's Class A common stock and has sold voting

and investment power regarding the shares held by NB Holdings.

Moderna said Tuesday that the FDA will not review its application for his experimental flu vaccine,

called MRNA 1010.

Instead, the agency issued what's known as a refusal to file letter.

Moderna is down 9% in pre-market action.

In a letter dated February 3rd, the FDA told the biotech company that the application

did not include what it considers an adequate and well-controlled

trial. Specifically, the agency said the study's comparison group did not reflect the best available

standard of care in the U.S. at the time the trial was conducted. Moderna said the FDA did not raise

any specific concerns about the vaccine safety or effectiveness.

The company also said the decision was inconsistent with earlier written feedback it had received from the agency.

Moderna has requested a meeting with the FDA officials to clarify its next steps.

Despite the setback, Moderna said it does not expect the decision to affect its 2026 financial

guidance. Estee Lauder is suing Walmart for selling counterfeit versions of its licensed

products. The cosmetics company claims third parties on Walmart's website were selling

counterfeit versions of LaMere, Clinique, Aveda, and Tom Ford products. And although Walmart

did not sell the products directly, Estee Lauder's lawsuit accuses the company of facilitating these

...